专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007110705A3 MACROLIDE AS INHIBITORS OF MHC CLASS II 审中-公开
标题翻译：作为MHC类II的抑制剂的MACROLIDE
公开(公告)号：WO2007110705A3
公开(公告)日：2007-11-29
申请号：PCT/IB2006004214
申请日：2006-09-27
申请人： NOVIMMUNE SA , MERLION PHARMACEUTICALS PTE LT , MACH BERNARD , TRAXLER PETER , MASTERNAK KRZYSZTOF , BUSS ANTONY DAVID , WHITTON STEPHEN ROBERT , BUTLER MARK STUART , KANAGASUNDARAM YOGONATHAN , FLOTOW HORST , XUMING GUO , SIM MUI MUI , PHOON CHEE WEE
发明人： MACH BERNARD , TRAXLER PETER , MASTERNAK KRZYSZTOF , BUSS ANTONY DAVID , WHITTON STEPHEN ROBERT , BUTLER MARK STUART , KANAGASUNDARAM YOGONATHAN , FLOTOW HORST , XUMING GUO , SIM MUI MUI , PHOON CHEE WEE
IPC分类号： C07D313/00 , A61K31/335 , A61K31/435 , A61K31/495 , A61K31/535 , A61K31/55 , A61P35/00 , A61P37/00 , C07D405/14 , C07D407/06
CPC分类号： C07D407/06 , C07D313/00 , C07D405/14
摘要： The present invention provides macrolide compounds, and pharmaceutically acceptable salts thereof, that inhibit MHC class II expression and that can be used as immunosuppressive agents in the treatment prior to, during and/or after organ or tissue transplantation, as well as in the treatment of immune-related disorders and/or cancer and cancer-related disorders.
摘要翻译：本发明提供了抑制MHC II类表达的大环内酯类化合物及其药学上可接受的盐，并且可以在器官或组织移植之前，期间和/或之后的治疗中用作免疫抑制剂，以及治疗免疫相关疾病和/或癌症和癌症相关疾病。

2. 发明申请

WO2003013541A1 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES 审中-公开
标题翻译： 4-氨基-6-苯基 - 吡咯并[2,3-D]吡啶衍生物
公开(公告)号：WO2003013541A1
公开(公告)日：2003-02-20
申请号：PCT/EP2002/008780
申请日：2002-08-06
申请人： NOVARTIS AG , NOVARTIS PHARMA GmbH , BOLD, Guido , CAPRARO, Hans-Georg , CARAVATTI, Giorgio , TRAXLER, Peter
发明人： BOLD, Guido , CAPRARO, Hans-Georg , CARAVATTI, Giorgio , TRAXLER, Peter
IPC分类号： A61K31/519
CPC分类号： C07D487/04
摘要： The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour.
摘要翻译：本发明涉及式I的7H-吡咯并[2,3-d]嘧啶衍生物，其中符号和取代基如说明书中所定义，其制备方法，包含该衍生物的药物组合物及其用途衍生物 - 单独或与一种或多种其它药学活性化合物组合 - 用于制备用于治疗特别是增殖性疾病如肿瘤的药物组合物。

3. 发明申请

WO2005120513A1 PROTEIN KINASE INHIBITORS 审中-公开
标题翻译：蛋白激酶抑制剂
公开(公告)号：WO2005120513A1
公开(公告)日：2005-12-22
申请号：PCT/CH2005/000321
申请日：2005-06-09
申请人： ESBATECH AG , BERSET, Catherine , AUDETAT, Stephan , TIETZ, Julia , GUNDE, Tea , BARBERIS, Alcide , SCHUMACHER, Andreas , TRAXLER, Peter
发明人： BERSET, Catherine , AUDETAT, Stephan , TIETZ, Julia , GUNDE, Tea , BARBERIS, Alcide , SCHUMACHER, Andreas , TRAXLER, Peter
IPC分类号： A61K31/519
CPC分类号： A61K31/519 , A61K31/695
摘要： The present invention relates to the use of compounds for the treatment of disorders involving a protein kinase, preferably a tyrosine kinase. The compounds e.g. have the general formula (I) wherein R 1 , R 2 and R 4 are independently selected from hydrogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, NR 6 R 7 , OR 6 , SR 6 , (CH) m R 6 R 7 , wherein R 6 and R 7 are independently selected from hydrogen, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted aryl, optionally substituted 5- or 6- membered heterocycle, (CH 2 ) n CO(O)R 8 , (CH 2 ) m R' where n = 0, 1, 2, 3, 4 and wherein R 8 is hydrogen, C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted aryl and wherein R' is selected from hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, optionally substituted aryl, halogen, hydroxyl, NO 2 , NH 2 , SO 2 NH 2 , cyano and m is 0, 1, 2, 3, 4; R 3 is hydroxyl, halogen, NH 2 , NO 2 , cyano, SH, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted aryl, optionally substituted 5- or 6-membered heterocycle, R 5 is selected from C 1 -C 6 alkyl, hydrogen, alkoxy, NH 2 , halogen, cyano, alkine, COOR'' wherein R'' is selected from hydrogen, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl.
摘要翻译：本发明涉及化合物用于治疗涉及蛋白激酶，优选酪氨酸激酶的病症的用途。化合物例如具有通式（I）其中R 1，R 2和R 4独立地选自氢，任选取代的C 1 -C 6烷基，任选取代的C 3 -C 8环烷基，NR 6 R 7，OR 6，SR 6，（CH）m R 6 R 7，其中R 6和R 7独立地选自氢，任选取代的C 3 -C 8环烷基，任选取代的芳基，任选取代的5-或6-元杂环，（CH 2）n CO（O）R 8，（CH 2）m R'，其中n = 0,1,2,3， 4，并且其中R 8是氢，C 1 -C 6烷基，任选取代的C 3 -C 8环烷基，任选取代的芳基，并且其中R'选自氢，C 1 -C 6烷基，C 1 -C 6烷氧基，任选取代的芳基，卤素，羟基，NO 2 ，NH2，SO2NH2，氰基和m是0,1,2,3,4; R3是羟基，卤素，NH2，NO2，氰基，SH，任选取代的C 1 -C 6烷基，任选取代的C 3 -C 8环烷基，任选取代的芳基，任选取代的5-或6-元杂环，R 5选自C 1 -C 6烷基，氢，烷氧基，NH 2，卤素，氰基，烷基，COOR“，其中R”选自氢，C 1 -C 6烷基，C 3 -C 8环烷基。

4. 发明申请

WO1998017662A1 PHENYL-SUBSTITUTED BICYCLIC HETEROCYCLYL DERIVATIVES AND THEIR USE 审中-公开
标题翻译：苯基取代的双环杂环衍生物及其用途
公开(公告)号：WO1998017662A1
公开(公告)日：1998-04-30
申请号：PCT/EP1997005697
申请日：1997-10-16
申请人： NOVARTIS AG , TRAXLER, Peter , SEQUIN, Urs , GREEN, Jennifer, Mary , FURET, Pascal
发明人： NOVARTIS AG
IPC分类号： C07D311/36
CPC分类号： C07D215/233 , A61K31/352 , C07D311/36
摘要： The invention relates to the use of a compound of formula (I), wherein R1 and R2, independently of each other, represent hydrogen, hydroxy or lower alkoxy, or R1 and R2 together form lower alkylenedioxy; R3 is halogen, lower alkyl, halogen-substituted lower alkyl, hydroxy, phenyloxy, C3-C7-cycloalkyloxy or lower alkoxy; any R4 is, independently of R3 and independently of any other R4 if present, selected from halogen, lower alkyl, halogen-substituted lower alkyl, hydroxy, phenyloxy, C3-C7-cycloalkyloxy or lower alkoxy; X is oxygen, imino or (halogen-substituted or unsubstituted lower alkanoyl, [lower alkyl or carboxy-, lower alkoxycarbonyl-, aminocarbonyl-, N-mono- or N,N-di-lower alkylamino carbonyl]-lower alkyl; or C6-C12-aryl)-substituted imino; and n is 0, 1, 3 or 4; or a salt thereof if at least one salt-forming group is present, in the treatment of certain diseases and the inhibition of protein kinases, as well as to new compounds of formula (I) and salts thereof.
摘要翻译：本发明涉及式（I）化合物的用途，其中R 1和R 2彼此独立地表示氢，羟基或低级烷氧基，或者R 1和R 2一起形成低级亚烷基二氧基; R3是卤素，低级烷基，卤素取代的低级烷基，羟基，苯氧基，C3-C7-环烷氧基或低级烷氧基; 任何R 4独立地为R 3，独立地为任何其它R 4（如果存在），选自卤素，低级烷基，卤素取代的低级烷基，羟基，苯氧基，C 3 -C 7 - 环烷氧基或低级烷氧基; X是氧，亚氨基或（卤素取代或未取代的低级烷酰基，[低级烷基或羧基 - ，低级烷氧基羰基 - ，氨基羰基 - ，N-单 - 或N，N-二 - 低级烷基氨基羰基] - 低级烷基;或C6 -C 12 - 芳基） - 取代的亚氨基; n为0,1,3或4; 如果存在至少一种成盐基团，则可以使用它们的盐，以治疗某些疾病和抑制蛋白激酶，以及新的式（I）化合物及其盐。

5. 发明申请

WO1998014451A1 FUSED PYRAZOLE DERIVATIVE AND PROCESS FOR ITS PREPARATION 审中-公开
标题翻译：熔融吡唑衍生物及其制备方法
公开(公告)号：WO1998014451A1
公开(公告)日：1998-04-09
申请号：PCT/EP1997005377
申请日：1997-09-30
申请人： NOVARTIS AG , BOLD, Guido , FREI, Jörg , LANG, Marc , TRAXLER, Peter , FURET, Pascal
发明人： NOVARTIS AG
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： 3-(3-Aminobenzylamino)-4-(3-chlorophenylamino)-1H-pyrazolo[3,4-d]pyrim idine of formula (I) is described. The compound of formula (I) inhibits, in particular, tyrosine-kinase activity of the receptor for the epidermal growth factor and can be used, for example, as antitumour agent and in cases of epidermal hyperproliferation (psoriasis).
摘要翻译：描述了式（I）的3-（3-氨基苄基氨基）-4-（3-氯苯基氨基）-1H-吡唑并[3,4-d]嘧啶。式（I）的化合物特别地抑制表皮生长因子受体的酪氨酸激酶活性，并且可以用作例如抗肿瘤剂和表皮过度增生（牛皮癣）的情况。

6. 发明申请

WO2009023978A1 PYRAZOLO [3,4 -D] PYRIMIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF PROTEIN KINASE 审中-公开
标题翻译：吡咯并[3,4-D]吡嗪化合物及其作为蛋白激酶调节剂的用途
公开(公告)号：WO2009023978A1
公开(公告)日：2009-02-26
申请号：PCT/CH2008/000348
申请日：2008-08-14
申请人： ONCALIS AG , LÜTHI, Urs , BERSET, Catherine , SCHMID, Gerhard , CAPRARO, Hans-Georg , TRAXLER, Peter Martin
发明人： LÜTHI, Urs , BERSET, Catherine , SCHMID, Gerhard , CAPRARO, Hans-Georg , TRAXLER, Peter Martin
IPC分类号： C07D487/04 , A61K31/519 , A61P35/00
CPC分类号： C07D487/04
摘要： The invention relates to pyrazolo[3,4-d]pyrimidine compounds of formula (I) and its salts wherein the substitents are as defined in the specification, their use for the treatment of protein kinase modulation responsive diseases or in the manufacture of pharmaceutical preparations useful in the treatment of said diseases, pharmaceutical preparations, especially useful against said diseases, comprising said compounds and a pharmaceutically acceptable carrier, said compounds for use in the treatment of the animal or human body, especially against said diseases, methods of treatment of the animal or human body comprising administering said compounds to an animal or human, and processes for the manufacture of said compounds.
摘要翻译：本发明涉及式（I）的吡唑并[3,4-d]嘧啶化合物及其盐，其中取代基如本说明书中所定义，其用于治疗蛋白激酶调节反应性疾病或用于制备药物制剂可用于治疗所述疾病，特别可用于所述疾病的药物制剂，其包含所述化合物和药学上可接受的载体，所述化合物用于治疗动物或人体，特别是针对所述疾病，治疗所述疾病的方法动物或人体，包括向动物或人施用所述化合物，以及制备所述化合物的方法。

7. 发明申请

WO2007110704A3 MACROLIDE COMPOSITIONS AS THERAPEUTIC AGENT 审中-公开
标题翻译：作为治疗剂的MACROLIDE组合物
公开(公告)号：WO2007110704A3
公开(公告)日：2008-02-14
申请号：PCT/IB2006004213
申请日：2006-09-27
申请人： NOVIMMUNE SA , MERLION PHARMACEUTICALS PTE LT , MACH BERNARD , TRAXLER PETER , MASTERNAK KRZYSZTOF , FLOTOW HORST , XUMING GUO , SIM MUI MUI , PHOON CHEE WEE
发明人： MACH BERNARD , TRAXLER PETER , MASTERNAK KRZYSZTOF , FLOTOW HORST , XUMING GUO , SIM MUI MUI , PHOON CHEE WEE
IPC分类号： C07D313/00 , A61K31/365 , A61P37/00 , C07D405/14 , C07D407/06
CPC分类号： C07D405/14 , C07D407/06
摘要： The present invention provides macrolide compounds, and pharmaceutically acceptable salts thereof, that inhibit MHC class II expression and that can be used as immunosuppressive agents in the treatment prior to, during and/or after organ or tissue transplantation, as well as in the treatment of immune-related disorders and/or cancer and cancer-related disorders.
摘要翻译：本发明提供了抑制MHC II类表达的大环内酯类化合物及其药学上可接受的盐，并且可以在器官或组织移植之前，期间和/或之后的治疗中用作免疫抑制剂，以及用于治疗免疫相关疾病和/或癌症和癌症相关疾病。

8. 发明申请

WO03013541A8 4-AMINO-6-PHENYL-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES 审中-公开
标题翻译： 4-氨基-6-苯基 - 吡咯并[2,3-D]吡啶衍生物
公开(公告)号：WO03013541A8
公开(公告)日：2004-02-26
申请号：PCT/EP0208780
申请日：2002-08-06
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BOLD GUIDO , CAPRARO HANS-GEORG , CARAVATTI GIORGIO , TRAXLER PETER
发明人： BOLD GUIDO , CAPRARO HANS-GEORG , CARAVATTI GIORGIO , TRAXLER PETER
IPC分类号： A61K31/519 , A61K31/5377 , A61P35/00 , A61P43/00 , C07D487/04
CPC分类号： C07D487/04
摘要： The invention relates to 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I wherein the symbols and substituents are as defined in the description, to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives-alone or in combination with one or more other pharmaceutically active compounds-for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour.
摘要翻译：本发明涉及式I的7H-吡咯并[2,3-d]嘧啶衍生物，其中符号和取代基如说明书中所定义，其制备方法，包含该衍生物的药物组合物及其用途衍生物 - 单独或与一种或多种其它药学活性化合物组合 - 用于制备用于治疗特别是增殖性疾病如肿瘤的药物组合物。

9. 发明申请

WO02067941A8 COMBINATION COMPRISING A SIGNAL TRANSDUCTION INHIBITOR AND AN EPOTHILONE DERIVATIVE 审中-公开
标题翻译：包含信号传导抑制剂和埃博霉素衍生物的组合
公开(公告)号：WO02067941A8
公开(公告)日：2003-12-18
申请号：PCT/EP0202049
申请日：2002-02-26
申请人： NOVARTIS AG , NOVARTIS PHARMA GMBH , BRANDT RALF , BUCHDUNGER ELISABETH , HELDIN CARL-HENRIK , OESTMAN ARNE , PIETRAS KRISTIAN , O'REILLY TERENCE , ROTHERMEL JOHN DAVID , TRAXLER PETER , WARTMANN MARKUS
发明人： BRANDT RALF , BUCHDUNGER ELISABETH , HELDIN CARL-HENRIK , OESTMAN ARNE , PIETRAS KRISTIAN , O'REILLY TERENCE , ROTHERMEL JOHN DAVID , TRAXLER PETER , WARTMANN MARKUS
IPC分类号： A61K45/00 , A61K31/425 , A61K31/427 , A61K31/505 , A61K31/506 , A61K31/519 , A61K45/06 , A61P35/00 , A61P43/00
CPC分类号： A61K31/505 , A61K31/425 , A61K45/06 , A61K31/435 , A61K2300/00
摘要： The invention relates to a combination which comprises (a) a signal transduction inhibitor selected from a PDGF (platelet-derived growth factor) receptor tyrosine kinase inhibitor and an active ingredient which decreases the activity of the epidermal growth factor (EGF) an epothilone derivative of formula (I) in which compound A represents O or NR n, wherein Rn is hydrogen or lower alkyl, R is hydrogen or lower alkyl, and Z is O or a bond, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular, for the delay of progression or treatment of a proliferative disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the delay of progression or treatment of a proliferative disease; a commercial package comprising such a combination as a combined preparation; and to a method of treatment of a warm-blooded animal.
摘要翻译：本发明涉及一种组合，其包含（a）选自PDGF（血小板衍生生长因子）受体酪氨酸激酶抑制剂和降低表皮生长因子（EGF）活性的活性成分的信号转导抑制剂，其中化合物A代表O或NRn，其中Rn为氢或低级烷基，R为氢或低级烷基，Z为O或键的化学式（I），以及任选的至少一种药学上可接受的载体用于同时，分开或顺序使用，特别是延迟增殖性疾病的进展或治疗; 包含这种组合的药物组合物; 这种组合用于制备用于延缓疾病进展或治疗增殖性疾病的药物的用途; 包含作为组合制剂的这种组合的商业包装; 并涉及一种治疗温血动物的方法。

10. 发明申请

WO1998014450A1 PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF 审中-公开
标题翻译：吡嗪衍生物及其制备方法
公开(公告)号：WO1998014450A1
公开(公告)日：1998-04-09
申请号：PCT/EP1997005369
申请日：1997-09-30
申请人： NOVARTIS AG , BOLD, Guido , FREI, Jörg , LANG, Marc , TRAXLER, Peter
发明人： NOVARTIS AG
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： 4-Amino-1H-pyrazolo[3,4-d]pyrimidine derivatives of formula (I) wherein the substituents are as defined in claim 1, are described. These compounds inhibit the tyrosine kinase activity of the receptor for epidermal growth factor (EGF) and c-erbB2 kinase and can be used as anti-tumour agents.
摘要翻译：描述了其中取代基如权利要求1中所定义的式（I）的4-氨基-1H-吡唑并[3,4-d]嘧啶衍生物。这些化合物抑制表皮生长因子（EGF）和c-erbB2激酶受体的酪氨酸激酶活性，可用作抗肿瘤剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式